Literature DB >> 29539427

Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression.

Filippo Cortesi1, Gloria Delfanti1, Andrea Grilli2, Arianna Calcinotto3, Francesca Gorini1, Ferdinando Pucci4, Roberta Lucianò5, Matteo Grioni3, Alessandra Recchia6, Fabio Benigni7, Alberto Briganti7, Andrea Salonia8, Michele De Palma9, Silvio Bicciato10, Claudio Doglioni11, Matteo Bellone12, Giulia Casorati13, Paolo Dellabona14.   

Abstract

Heterotypic cellular and molecular interactions in the tumor microenvironment (TME) control cancer progression. Here, we show that CD1d-restricted invariant natural killer (iNKT) cells control prostate cancer (PCa) progression by sculpting the TME. In a mouse PCa model, iNKT cells restrained the pro-angiogenic and immunosuppressive capabilities of tumor-infiltrating immune cells by reducing pro-angiogenic TIE2+, M2-like macrophages (TEMs), and sustaining pro-inflammatory M1-like macrophages. iNKT cells directly contacted macrophages in the PCa stroma, and iNKT cell transfer into tumor-bearing mice abated TEMs, delaying tumor progression. iNKT cells modulated macrophages through the cooperative engagement of CD1d, Fas, and CD40, which promoted selective killing of M2-like and survival of M1-like macrophages. Human PCa aggressiveness associate with reduced intra-tumoral iNKT cells, increased TEMs, and expression of pro-angiogenic genes, underscoring the clinical significance of this crosstalk. Therefore, iNKT cells may control PCa through mechanisms involving differential macrophage modulation, which may be harnessed for therapeutically reprogramming the TME.
Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD1d; CD40; Fas; angiogenesis; iNKT cells; immunotherapy; macrophage; prostate cancer; tumor microenvironment

Mesh:

Substances:

Year:  2018        PMID: 29539427     DOI: 10.1016/j.celrep.2018.02.058

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  22 in total

Review 1.  Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment.

Authors:  Gloria Delfanti; Paolo Dellabona; Giulia Casorati; Maya Fedeli
Journal:  Front Med (Lausanne)       Date:  2022-05-09

2.  IL10 Secretion Endows Intestinal Human iNKT Cells with Regulatory Functions Towards Pathogenic T Lymphocytes.

Authors:  Claudia Burrello; Francesco Strati; Georgia Lattanzi; Angelica Diaz-Basabe; Erika Mileti; Maria Rita Giuffrè; Gianluca Lopez; Fulvia Milena Cribiù; Elena Trombetta; Marinos Kallikourdis; Marco Cremonesi; Francesco Conforti; Fiorenzo Botti; Laura Porretti; Maria Rescigno; Maurizio Vecchi; Massimo C Fantini; Flavio Caprioli; Federica Facciotti
Journal:  J Crohns Colitis       Date:  2022-09-08       Impact factor: 10.020

3.  Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Authors:  Yanni Zhu; Drake J Smith; Yang Zhou; Yan-Ruide Li; Jiaji Yu; Derek Lee; Yu-Chen Wang; Stefano Di Biase; Xi Wang; Christian Hardoy; Josh Ku; Tasha Tsao; Levina J Lin; Alexander T Pham; Heesung Moon; Jami McLaughlin; Donghui Cheng; Roger P Hollis; Beatriz Campo-Fernandez; Fabrizia Urbinati; Liu Wei; Larry Pang; Valerie Rezek; Beata Berent-Maoz; Mignonette H Macabali; David Gjertson; Xiaoyan Wang; Zoran Galic; Scott G Kitchen; Dong Sung An; Siwen Hu-Lieskovan; Paula J Kaplan-Lefko; Satiro N De Oliveira; Christopher S Seet; Sarah M Larson; Stephen J Forman; James R Heath; Jerome A Zack; Gay M Crooks; Caius G Radu; Antoni Ribas; Donald B Kohn; Owen N Witte; Lili Yang
Journal:  Cell Stem Cell       Date:  2019-09-05       Impact factor: 24.633

4.  An integrated analysis of human myeloid cells identifies gaps in in vitro models of in vivo biology.

Authors:  Nadia Rajab; Paul W Angel; Yidi Deng; Jennifer Gu; Vanta Jameson; Mariola Kurowska-Stolarska; Simon Milling; Chris M Pacheco; Matt Rutar; Andrew L Laslett; Kim-Anh Lê Cao; Jarny Choi; Christine A Wells
Journal:  Stem Cell Reports       Date:  2021-05-13       Impact factor: 7.765

Review 5.  Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance.

Authors:  Rongbin Ge; Zongwei Wang; Liang Cheng
Journal:  NPJ Precis Oncol       Date:  2022-05-04

Review 6.  The Remarkable Plasticity of Macrophages: A Chance to Fight Cancer.

Authors:  Nadège Bercovici; Marion V Guérin; Alain Trautmann; Emmanuel Donnadieu
Journal:  Front Immunol       Date:  2019-07-12       Impact factor: 7.561

7.  Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy.

Authors:  Adriana C Vidal; Lauren E Howard; Emily Wiggins; Amanda M De Hoedt; Stephen L Shiao; Simon Knott; Emanuela Taioli; Jay H Fowke; Stephen J Freedland
Journal:  Cancer Epidemiol       Date:  2019-08-01       Impact factor: 2.984

Review 8.  Targeting Natural Killer T Cells in Solid Malignancies.

Authors:  Zewde Ingram; Shriya Madan; Jenoy Merchant; Zakiya Carter; Zen Gordon; Gregory Carey; Tonya J Webb
Journal:  Cells       Date:  2021-05-27       Impact factor: 6.600

Review 9.  The Pathophysiological Relevance of the iNKT Cell/Mononuclear Phagocyte Crosstalk in Tissues.

Authors:  Filippo Cortesi; Gloria Delfanti; Giulia Casorati; Paolo Dellabona
Journal:  Front Immunol       Date:  2018-10-12       Impact factor: 7.561

10.  Natural killer T cell activation increases iNOS+CD206- M1 macrophage and controls the growth of solid tumor.

Authors:  Sourav Paul; Sushanta Chhatar; Amrita Mishra; Girdhari Lal
Journal:  J Immunother Cancer       Date:  2019-08-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.